Related Experiment Video
Updated: May 14, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Anemia and left ventricular hypertrophy with renal function decline and cardiovascular events in chronic kidney
Jer-Ming Chang1, Szu-Chia Chen, Jiun-Chi Huang
1Division of Nephrology (J-MC, S-CC, J-CH, H-CC); and Division of Cardiology (H-MS), Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Internal Medicine (J-MC, S-CC, J-CH, H-MS), Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Faculty of Renal Care (J-MC, H-CC); and Faculty of Medicine (S-CC, H-MS), College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Insights
Anemia and left ventricular hypertrophy (LVH) in chronic kidney disease (CKD) patients independently predict faster kidney function decline and higher cardiovascular event risk. Early assessment aids in identifying high-risk individuals.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Anemia is a frequent complication in chronic kidney disease (CKD).
- Anemia may initiate or accelerate left ventricular hypertrophy (LVH).
- The independent association of coexisting anemia and LVH with renal function decline and cardiovascular events in CKD patients requires investigation.
Purpose of the Study:
- To assess if coexisting anemia and LVH are independently associated with the rate of renal function decline in CKD stages 3 to 5.
- To determine if coexisting anemia and LVH are independently associated with increased cardiovascular events in CKD stages 3 to 5.
Main Methods:
- Longitudinal study of 415 CKD patients (stages 3-5).
- Patients classified into 4 groups based on hemoglobin levels and presence/absence of LVH.
- Renal function change measured by estimated glomerular filtration rate (eGFR) slope; cardiovascular events defined and analyzed using Cox regression.
Main Results:
- The eGFR slope was significantly lower in patients with both low hemoglobin and LVH compared to other groups (P ≤ 0.031).
- Coexisting anemia and LVH were independently associated with a 4.269-fold increased risk of cardiovascular events (HR, 4.269; P = 0.011).
Conclusions:
- The coexistence of anemia and LVH is independently linked to accelerated renal function decline and adverse cardiovascular outcomes in CKD patients.
- Serum hemoglobin levels and LVH assessment via echocardiography can identify high-risk CKD patients with poor renal and cardiovascular prognosis.
Background:
Anemia is a common complication in patients with chronic kidney disease (CKD), which may initiate or accelerate left ventricular hypertrophy (LVH). This study is designed to assess whether the coexistence of anemia and LVH is independently associated with the rate of renal function decline and increased cardiovascular events in patients with CKD stages 3 to 5.
Methods:
This longitudinal study enrolled 415 patients, who were classified into 4 groups according to sex-specific median values of hemoglobin and with/without LVH. The change in renal function was measured by estimated glomerular filtration rate slope. Cardiovascular events were defined as cardiovascular death, hospitalization for unstable angina, nonfatal myocardial infarction, sustained ventricular arrhythmia, hospitalization for congestive heart failure, transient ischemia attack, and stroke. The relative risk of cardiovascular events was analyzed by Cox's regression method.
Results:
The estimated glomerular filtration rate slope was significantly lower in the group with lower hemoglobin and LVH than in the other groups (P ≤ 0.031). In addition, patients with lower hemoglobin and LVH were independently associated with increased cardiovascular events (hazard ratio, 4.269; 95% confidence interval, 1.402-13.000; P = 0.011).
Conclusions:
Our findings showed that the coexistence of anemia and LVH was independently associated with faster renal function decline and poor cardiovascular outcomes in patients with CKD. Assessments of serum hemoglobin level and LVH by echocardiography may help identify a high-risk group of poor renal and cardiovascular prognosis in patients with CKD stages 3 to 5.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Heart Failure II: Pathophysiology
Diabetic Nephropathy
Heart Failure III: Clinical Manifestations
